Myriad misses, cuts 2026 sales outlook and suspends EBITDA targets

 

Myriad Genetics misses Q2 2026 estimates with non-GAAP EPS -$0.25, revenue $190.7M, cuts 2026 sales outlook and suspends EBITDA targets

• Q2 2026 non-GAAP EPS -$0.25 represented a -600% year-over-year change from prior-year period
• Q2 2026 revenue declined 11% year-over-year to $190.7M
• Company cut 2026 sales outlook to a range of $770M to $790M

https://finviz.com/stock?t=MYGN&p=d